In the tumor microenvironment, the PD-1 receptor is highly N-glycosylated in T cells, thereby maintaining PD-1 stability and interaction with the PD-L1 ligand expressed in tumor cells and dampening the activity of T-cell receptor (TCR)/CD28) signals [105]. Here, CD28 is linked to neoplasm.